Literature DB >> 12378454

Follow-up of partial splenectomy in children with hereditary spherocytosis.

A S de Buys Roessingh1, P de Lagausie, P Rohrlich, D Berrebi, Y Aigrain.   

Abstract

BACKGROUND/
PURPOSE: The aim of this report is to study the short- and long-term consequences of partial splenectomy (PS) in hereditary spherocytosis (HS).
METHODS: The authors reviewed the files of 5 children who underwent PS from 1993 to 1998. The data collected included clinical presentation, age, gender, indication for the operation, radiographic examination, need for blood transfusion and hematologic values, description of surgical procedure, and early- and late-occurring complications.
RESULTS: From 1993 to 1998, 5 children from one year, 9 months to 7 years of age underwent PS. Indications were hypersplenism and severe anemia. The average age at the time of the operation was 3 years, 5 months. The 2 youngest children (one year, 9 months and 2 years old) needed a second operation because of the recurrence of hypersplenism.
CONCLUSIONS: Subtotal splenectomy seems to preserve the immune role of the spleen and can reduce the need for blood transfusion. But PS is associated with a regrowth of the splenic remnant in children suffering from chronic hemolysis with hypersplenism and seems to be effective for a relatively short period only, especially in young children. Thus, a second operation to perform a total splenectomy can be necessary. The decision to perform a PS on young children with HS as an alternative to total splenectomy with appropriate preoperative vaccination and postoperative prophylactic antibiotics therefore should be weighed carefully, keeping in mind, however, the benefit of postponing total splenectomy in these patients. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12378454     DOI: 10.1053/jpsu.2002.35412

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

1.  Laparoscopic versus robotic subtotal splenectomy in hereditary spherocytosis. Potential advantages and limits of an expensive approach.

Authors:  Catalin Vasilescu; Oana Stanciulea; Stefan Tudor
Journal:  Surg Endosc       Date:  2012-04-05       Impact factor: 4.584

2.  Pediatric splenectomy for hematological diseases: outcome analysis.

Authors:  C U Durakbasa; C Timur; V Sehiralti; M Mutus; N Tosyali; A Yoruk
Journal:  Pediatr Surg Int       Date:  2006-07-13       Impact factor: 1.827

3.  Laparoscopic ligation of splenic vessels for the treatment of hereditary spherocytosis in children.

Authors:  Jin-Shan Zhang; Long Li
Journal:  Pediatr Surg Int       Date:  2020-01-25       Impact factor: 1.827

4.  Partial splenectomy using a laparoscopic bipolar radiofrequency device: a case report.

Authors:  Wei-Dong Wang; Jie Lin; Zhi-Qiang Wu; Qing-Bo Liu; Jing Ma; Xiao-Wu Chen
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  Near-total splenectomy: a new technique for the management of hereditary spherocytosis.

Authors:  Gerhard A Stoehr; Urs G Stauffer; Stefan W Eber
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

6.  Laparoscopic distal pancreatectomy with splenic preservation.

Authors:  A Pryor; J R Means; T N Pappas
Journal:  Surg Endosc       Date:  2007-06-26       Impact factor: 4.584

Review 7.  Pediatric laparoscopic splenectomy: benefits of the anterior approach.

Authors:  P de Lagausie; A Bonnard; M Benkerrou; P Rorlich; A de Ribier; Y Aigrain
Journal:  Surg Endosc       Date:  2003-11-21       Impact factor: 4.584

8.  Super-Selective Partial Splenic Embolization for Hereditary Spherocytosis in Children: A Single-Center Retrospective Study.

Authors:  Rui-Jue Wang; Li Xiao; Xi-Ming Xu; Ming-Man Zhang; Qiang Xiong
Journal:  Front Surg       Date:  2022-02-25

9.  Laparoscopic partial splenectomy: indications and results of a multicenter retrospective study.

Authors:  Géraldine Héry; François Becmeur; Laure Méfat; David Kalfa; Patrick Lutz; Laurence Lutz; Jean-Michel Guys; Pascal de Lagausie
Journal:  Surg Endosc       Date:  2007-10-18       Impact factor: 3.453

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.